Business ❯ Market Competition

Pharmaceutical Industry

Eli Lilly Novo Nordisk Weight Loss Drugs Drug Development Product Launches Rivalry Competitor Analysis Vaccine Manufacturers Eli Lilly vs Novo Nordisk Investor Sentiment

Novo Nordisk Leans on Wegovy’s New MASH Indication and First Oral Obesity Pill to Rebound in 2026

The expanded labels create a path to recapture GLP-1 momentum after a tough 2025.

FDA Clears Wegovy Pill, Handing Novo Nordisk a Short-Term Edge in Obesity-Drug Race

Zealand Pharma Unveils ‘Metabolic Frontier 2030’ With Targets for Five Launches

Janux Plunges on Mixed Phase 1 Prostate Cancer Data for JANX007

Bayer’s Asundexian Cuts Recurrent Stroke Risk in Phase III Without More Major Bleeding

Eli Lilly Becomes First Health Care Company Valued at $1 Trillion

Roche Says Breast Cancer Pill Cuts Recurrence in Phase 3 Adjuvant Trial

Lilly’s Oral GLP-1 Orforglipron Beats Farxiga and Placebo in Two Phase 3 Diabetes Trials

Novo Nordisk Cuts 9,000 Jobs as It Lowers 2025 Margin Outlook

Eli Lilly’s Oral Obesity Pill Triggers Stock Slide After Modest Weight-Loss Results

Eli Lilly Raises 2025 Outlook as Tirzepatide Sales Soar, Orforglipron Misses Marks

Wegovy Prescriptions Surge as FDA Ban Cuts Into Copycats

Novo Nordisk CEO Steps Down Following Share Price Collapse

Eli Lilly Reports Record Q1 Revenue but Faces Profit Pressure and Competitive Challenges

Pfizer Halts Development of Danuglipron After Liver Safety Concerns

Novo Nordisk Faces Investor Turmoil as Wegovy Sales and Market Share Decline

Novavax Reports Narrower Q4 Loss and Strategic Shift Away from COVID-19 Vaccine Commercialization

Eli Lilly Lowers 2024 Revenue Forecast Due to Slower Weight-Loss Drug Growth

Novo Nordisk's Amycretin Shows Promise as Next-Gen Weight Loss Drug